Abstract
Importance There is conflicting evidence about the role of angiotensin converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) in the pathogenesis and outcome of patients infected with acute severe respiratory syndrome coronavirus 2 (SARS-CoV-2) and growing public concerns about their use during this pandemic.
Objective We sought to systematically review the literature and perform a meta-analysis about prior use of ACEI/ARBs and outcome of COVID-19 patients.
Data source We searched multiple data sources including PubMed, ClinicalTrial.org, and medrxiv.org from November 2019 through May 3, 2020.
Study selection Any study that reported on the role of ACEIs / ARBs and outcome of COIVD-19 is eligible. Two authors independently reviewed eligible studies and extracted data into a prespecified data collection form.
Data synthesis An inverse variance meta-analytic approach was used to pool adjusted odds ratios using a random effect model meta-analysis. I 2 test was used to assess in between studies heterogeneity. The Newcastle-Ottawa quality assessment scale was used to assess the quality of included studies.
Main outcome and Measures The association between the prior use of ACEIs / ARBs and the mortality among SARS-CoV-2 infected patients was assessed using pooled OR and 95% confidence interval. For studies that did not report adjusted effect estimates for mortality, we used their adjusted effect estimate of critical outcome to estimate another pooled OR for critical or fatal outcome and its 95% confidence interval.
Results Nine studies were included in this systematic review. The studies included a total of 58,615 patients infected with SARS-CoV-2. Prior use of ACEIs and/or ARBs was associated with a significant reduction of inpatient mortality among SARS-CoV-2 infected patients, with a pooled adjusted OR from 4 studies of 0.33, 95% CI [0.22, 0.49] with no between studies heterogeneity (12=0%) and with a significant reduction of critical or fatal outcome, with a pooled adjusted OR from 5 studies of 0.32, 95% CI [0.22, 0.46] (12 =32%).
Conclusion Our meta-analysis suggests that use of ACEIs/ARBs is associated with a decreased risk of death or critical outcome among SARS-CoV-2 infected patients. This finding is limited by the observational nature of the included studies. However, it provides a reassurance to the public not to stop prescribed ACEIs/ARBs due to fear of severe COVID-19. It also calls upon investigators and ethics committees to reconsider the ongoing randomized trials of discontinuation of these drugs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding received.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
NA
